SCHEMBL1544551

SCHEMBL1544551

CC(C)O/C=C(/Br)C=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650579 1.00
SCHEMBL648003 1.00
SCHEMBL16327975 0.76
SCHEMBL13848749 0.72
SCHEMBL11163142 0.70
SCHEMBL8626148 0.70
SCHEMBL12704754 0.70
SCHEMBL11495563 0.70
SCHEMBL14297400 0.70
SCHEMBL13792239 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017069601-A1 SUBSTITUTED AMINOALKYLAZOLES AS MALARIAL ASPARTIC PROTEASE INHIBITORS LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2017-04-27 WO disclosed
EP-2640731-B9 IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS LUNDBECK & CO AS H (DK) 2015-11-25 EP disclosed
EP-2640731-B1 IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS LUNDBECK & CO AS H (DK) 2015-07-08 EP disclosed
US-9062060-B2 Substituted imidazo[2,1-A]isoindoles as PDE10 inhibitors H. LUNDBECK A/S (DK) 2015-06-23 US disclosed
US-9062060-B2 Substituted imidazo[2,1-A]isoindoles as PDE10 inhibitors H. LUNDBECK A/S (DK) 2015-06-23 US disclosed
US-20140357639-A1 Imidazole derivatives as PDE10 enzyme inhibitors H. LUNDBECK A/S (DK) 2014-12-04 US disclosed
US-20140357639-A1 Imidazole derivatives as PDE10 enzyme inhibitors H. LUNDBECK A/S (DK) 2014-12-04 US disclosed
US-8796304-B2 Tricyclic imidazole compounds as PDE10 inhibitors H. LUNDBECK A/S (DK) 2014-08-05 US disclosed
US-8796304-B2 Tricyclic imidazole compounds as PDE10 inhibitors H. LUNDBECK A/S (DK) 2014-08-05 US disclosed
US-8703776-B2 Agonists of GPR131 and uses thereof CYMABAY THERAPEUTICS, INC. (US) 2014-04-22 US disclosed
US-20070179188-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-02 US disclosed
US-20070179188-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-02 US disclosed
US-20070142371-A1 Anti-Cytokine Heterocyclic Compounds COGAN DEREK 2007-06-21 US disclosed
US-20070142371-A1 Anti-Cytokine Heterocyclic Compounds COGAN DEREK 2007-06-21 US disclosed
US-7214802-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-05-08 US disclosed
US-7214802-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-05-08 US disclosed
EP-1723144-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AstraZeneca AB (SE) 2006-11-22 EP disclosed
WO-2006014185-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2006-02-09 WO disclosed
WO-2006014185-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2006-02-09 WO disclosed
US-20050272779-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2005-12-08 US disclosed